Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA‐based or adenoviral vector‐based SARS‐CoV‐2 vaccination
Alexander Kreuter, Maximiliano J. Licciardi-Fernandez, Sven‐Niklas Burmann, B. Burkert, Frank Oellig, Alena‐Lioba Michalowitz
Abstract
Evidence is accumulating that COVID-19 vaccines might induce or exacerbate autoimmune rheumatic diseases. The currently available COVID-19 vaccines include mRNA and recombinant adenoviral vector vaccines, both encoding SARS-CoV-2 spike protein production as the primary target for neutralizing antibodies. We report a case of subacute cutaneous lupus erythematosus (SCLE) following mRNA vaccination with the Pfizer mRNA vaccine BNT162b2, and summarize the current literature on CLE occurring after COVID-19 vaccination.
Topics & Concepts
ExacerbationMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirus disease 2019 (COVID-19)Vaccination2019-20 coronavirus outbreakImmunologyVector (molecular biology)PathologyBiologyRecombinant DNAInfectious disease (medical specialty)OutbreakDiseaseGeneBiochemistrySystemic Lupus Erythematosus ResearchSARS-CoV-2 and COVID-19 ResearchDermatological and COVID-19 studies